| Serial Number | 79342263 |
| Word Mark | ILLIMIS |
| Filing Date | Thursday, March 17, 2022 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, July 4, 2023 |
| Registration Number | 7095522 |
| Registration Date | Tuesday, July 4, 2023 |
| Mark Drawing | 5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
| Published for Opposition Date | Tuesday, April 18, 2023 |
| Goods and Services | Pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical agents affecting sensory organs; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for activating cellular function; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for respiratory organs; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of inflammatory diseases; ophthalmic preparations; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of degenerative brain disease; pharmaceutical preparations for the treatment of brain dysfunction; pharmaceutical preparations for the treatment of stroke; pharmaceutical preparations for the treatment of cerebrovascular disease; pharmaceutical preparations for the treatment of dementia; pharmaceutical preparations for the treatment of Alzheimer's disease; pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders, amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders |
| Goods and Services | Pharmaceutical product development; pharmaceutical research and development of medicines in the field of age-related diseases/disorders and degenerative diseases; pharmaceutical research and development of medicines in the field of chronic malady/disease and dysfunction; scientific research for medical purposes in the field of gene therapy; medical scientific research in the field of brain disease; medical scientific research in the field of neurological diseases; biotechnology research and scientific and pharmaceutical research in the antibody field; biological research; scientific research in the field of cancer disease; remote monitoring and quality control inspection for others of active substances in the pharmaceutical research field and scientific analysis of active substances in the pharmaceutical research field; research for quality inspection related to human hygiene management for medical research purposes; scientific and medical research of autoimmune disease; development of pharmaceutical preparations for cell therapy; stem cell collection for medical research; cell processing and culture for medical research; pharmaceutical research and development of medicines in the field of inflammatory disease; pharmaceutical research and development of medicines in the field of eye disease; pharmaceutical research and development of medicines in the field of amyloidosis; consultancy pertaining to pharmacology relating to pharmaceutical quality control; providing information on the research of medical products relating to pharmaceutical quality control |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, June 10, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, June 10, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Illimis Therapeutics, Inc. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Party Name | Illimis Therapeutics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Party Name | Illimis Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Event Date | Event Description |
| Tuesday, October 31, 2023 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Friday, October 6, 2023 | FINAL DISPOSITION NOTICE SENT TO IB |
| Friday, October 6, 2023 | FINAL DISPOSITION PROCESSED |
| Wednesday, October 4, 2023 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Tuesday, July 4, 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, July 4, 2023 | REGISTERED-PRINCIPAL REGISTER |
| Wednesday, May 10, 2023 | LIMITATION FROM THE IB EXAMINED AND ENTERED |
| Tuesday, April 25, 2023 | NOTIFICATION PROCESSED BY IB |
| Tuesday, April 18, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, April 18, 2023 | PUBLISHED FOR OPPOSITION |
| Wednesday, April 5, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, April 5, 2023 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, March 29, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, March 21, 2023 | REFUSAL PROCESSED BY IB |
| Saturday, March 11, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, March 7, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, March 7, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, March 7, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, February 27, 2023 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Monday, February 27, 2023 | REFUSAL PROCESSED BY MPU |
| Monday, February 13, 2023 | LIMITATION OF GOODS RECEIVED FROM IB |
| Sunday, January 1, 2023 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Saturday, December 31, 2022 | NON-FINAL ACTION WRITTEN |
| Thursday, December 29, 2022 | ASSIGNED TO EXAMINER |
| Tuesday, June 14, 2022 | APPLICATION FILING RECEIPT MAILED |
| Friday, June 10, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, June 9, 2022 | SN ASSIGNED FOR SECT 66A APPL FROM IB |